ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protalix BioTherapeutics, Chiesi Global Announce BLA Acceptance of Pegunigalsidase Alfa
August 14, 2020Protalix BioTherapeutics together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted ... -
Protalix BioTherapeutics, Chiesi Complete Enrollment for Trial of Pegunigalsidase Alfa
September 25, 2019Protalix BioTherapeutics and its development and commercialization partner, Chiesi Farmaceutici announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa ...
Pharma Sources Insight January 2025
